JP2015504666A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504666A5 JP2015504666A5 JP2014550526A JP2014550526A JP2015504666A5 JP 2015504666 A5 JP2015504666 A5 JP 2015504666A5 JP 2014550526 A JP2014550526 A JP 2014550526A JP 2014550526 A JP2014550526 A JP 2014550526A JP 2015504666 A5 JP2015504666 A5 JP 2015504666A5
- Authority
- JP
- Japan
- Prior art keywords
- position corresponding
- polypeptide
- amino acid
- modified
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 51
- 229920001184 polypeptide Polymers 0.000 claims 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims 50
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 claims 43
- 101150055528 SPAM1 gene Proteins 0.000 claims 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims 37
- 238000006467 substitution reaction Methods 0.000 claims 32
- 239000003814 drug Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 12
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 9
- 239000003755 preservative agent Substances 0.000 claims 9
- 230000002335 preservative effect Effects 0.000 claims 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 230000021615 conjugation Effects 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 4
- 108010003272 Hyaluronate lyase Proteins 0.000 claims 4
- 102000001974 Hyaluronidases Human genes 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 229960002773 hyaluronidase Drugs 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- -1 α-adrenergic Substances 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000035484 Cellulite Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 206010049752 Peau d'orange Diseases 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims 2
- 229940034794 benzylparaben Drugs 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 230000036232 cellulite Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 210000003722 extracellular fluid Anatomy 0.000 claims 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 2
- 229920002674 hyaluronan Polymers 0.000 claims 2
- 229940099552 hyaluronan Drugs 0.000 claims 2
- 229940100630 metacresol Drugs 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- 102220182705 rs191061766 Human genes 0.000 claims 2
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 claims 1
- XWBADQOPXPRKBX-FMIVXFBMSA-N 1-n,1-n-diethyl-4-n-[6-methoxy-2-[(e)-2-(4-nitrophenyl)ethenyl]quinolin-4-yl]pentane-1,4-diamine Chemical compound N=1C2=CC=C(OC)C=C2C(NC(C)CCCN(CC)CC)=CC=1\C=C\C1=CC=C([N+]([O-])=O)C=C1 XWBADQOPXPRKBX-FMIVXFBMSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 241000224489 Amoeba Species 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- 102000008068 Tensins Human genes 0.000 claims 1
- 108010088950 Tensins Proteins 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000002456 anti-arthritic effect Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 230000002141 anti-parasite Effects 0.000 claims 1
- 229940035678 anti-parkinson drug Drugs 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 229940124350 antibacterial drug Drugs 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000003430 antimalarial agent Substances 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 239000003716 antitrichomonal agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000003899 bactericide agent Substances 0.000 claims 1
- 230000003385 bacteriostatic effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000003139 biocide Substances 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 229940019700 blood coagulation factors Drugs 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 230000021523 carboxylation Effects 0.000 claims 1
- 238000006473 carboxylation reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000033444 hydroxylation Effects 0.000 claims 1
- 238000005805 hydroxylation reaction Methods 0.000 claims 1
- 230000003345 hyperglycaemic effect Effects 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229940023490 ophthalmic product Drugs 0.000 claims 1
- 239000000734 parasympathomimetic agent Substances 0.000 claims 1
- 230000001499 parasympathomimetic effect Effects 0.000 claims 1
- 229940005542 parasympathomimetics Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- 230000009450 sialylation Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000001975 sympathomimetic effect Effects 0.000 claims 1
- 229940064707 sympathomimetics Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 239000003204 tranquilizing agent Substances 0.000 claims 1
- 230000002936 tranquilizing effect Effects 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161631313P | 2011-12-30 | 2011-12-30 | |
| US61/631,313 | 2011-12-30 | ||
| US201261796208P | 2012-11-01 | 2012-11-01 | |
| US61/796,208 | 2012-11-01 | ||
| PCT/US2012/072182 WO2013102144A2 (en) | 2011-12-30 | 2012-12-28 | Ph20 polypeptede variants, formulations and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016247708A Division JP6422933B2 (ja) | 2011-12-30 | 2016-12-21 | Ｐｈ２０ポリペプチド変異体、その製剤および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504666A JP2015504666A (ja) | 2015-02-16 |
| JP2015504666A5 true JP2015504666A5 (enExample) | 2015-03-26 |
| JP6067746B2 JP6067746B2 (ja) | 2017-01-25 |
Family
ID=47595052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014550526A Active JP6067746B2 (ja) | 2011-12-30 | 2012-12-28 | Ｐｈ２０ポリペプチド変異体、その製剤および使用 |
| JP2016247708A Active JP6422933B2 (ja) | 2011-12-30 | 2016-12-21 | Ｐｈ２０ポリペプチド変異体、その製剤および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016247708A Active JP6422933B2 (ja) | 2011-12-30 | 2016-12-21 | Ｐｈ２０ポリペプチド変異体、その製剤および使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (28) | US9447401B2 (enExample) |
| EP (2) | EP2797622B1 (enExample) |
| JP (2) | JP6067746B2 (enExample) |
| CN (1) | CN104244968B (enExample) |
| AU (2) | AU2012362141B2 (enExample) |
| BR (1) | BR112014016195A2 (enExample) |
| CA (1) | CA2861919C (enExample) |
| CY (1) | CY1122532T1 (enExample) |
| DK (2) | DK3130347T3 (enExample) |
| EA (1) | EA030252B9 (enExample) |
| ES (2) | ES2749620T3 (enExample) |
| HR (1) | HRP20192249T1 (enExample) |
| HU (1) | HUE047849T2 (enExample) |
| IL (5) | IL317266A (enExample) |
| LT (1) | LT3130347T (enExample) |
| MX (2) | MX361727B (enExample) |
| PL (1) | PL3130347T3 (enExample) |
| PT (1) | PT3130347T (enExample) |
| RS (1) | RS59703B1 (enExample) |
| SG (2) | SG10201604470TA (enExample) |
| SI (1) | SI3130347T1 (enExample) |
| SM (1) | SMT201900630T1 (enExample) |
| WO (1) | WO2013102144A2 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2517145C (en) | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| JP2011519361A (ja) | 2008-04-14 | 2011-07-07 | ハロザイム インコーポレイテッド | 修飾されたヒアルロニダーゼおよびヒアルロナン関連疾患および状態の治療における使用 |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| ES2724588T3 (es) * | 2008-12-09 | 2019-09-12 | Halozyme Inc | Polipéptidos de PH20 soluble extendida y usos de los mismos |
| US9084743B2 (en) | 2009-09-17 | 2015-07-21 | Baxter International Inc. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| KR20130125753A (ko) | 2010-07-20 | 2013-11-19 | 할로자임, 아이엔씨 | 항-히알루로난제 투여와 관련된 유해 부작용의 치료 |
| US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| KR20140043438A (ko) * | 2011-06-17 | 2014-04-09 | 할로자임, 아이엔씨 | 히알루로난 분해 효소의 안정한 제형 |
| EA030440B1 (ru) | 2011-10-24 | 2018-08-31 | Галозим, Инк. | Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения |
| BR112014016195A2 (pt) | 2011-12-30 | 2020-10-27 | Halozyme, Inc. | variantes de polipeptídio ph20, formulações e usos das mesmas |
| CN104411324A (zh) | 2012-04-04 | 2015-03-11 | 哈洛齐梅公司 | 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法 |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| WO2014076423A1 (fr) | 2012-11-13 | 2014-05-22 | Adocia | Formulation à action rapide d'insuline comprenant un composé anionique substitué |
| TW201534726A (zh) * | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ｐｈ２０玻尿酸酶變異體及其用途 |
| HUP1300646A2 (en) * | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| CN103819578B (zh) * | 2013-11-22 | 2016-05-11 | 青岛九龙生物医药有限公司 | 一种加氢氧化钠法提高硫酸软骨素收率的方法 |
| US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US20150328317A1 (en) * | 2014-05-13 | 2015-11-19 | Eagle Pharmaceuticals, Inc. | Aqueous buffer-free bivalirudin compositions |
| HRP20190881T1 (hr) | 2014-08-28 | 2019-07-12 | Halozyme, Inc. | Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke |
| EP3207130B1 (en) | 2014-10-14 | 2019-08-07 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
| EP3227338A4 (en) | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| AR102869A1 (es) | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| US10118904B2 (en) | 2015-06-05 | 2018-11-06 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of Demyelinating Diseases |
| JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| PL3827845T3 (pl) | 2015-11-03 | 2022-07-11 | Janssen Biotech, Inc. | Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania |
| CN105727267B (zh) * | 2016-02-05 | 2020-05-26 | 苏州康聚生物科技有限公司 | 一种重组人透明质酸酶冻干制剂及其制备方法和应用 |
| GB201607918D0 (en) * | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| WO2017201635A1 (zh) * | 2016-05-23 | 2017-11-30 | 蔡胜和 | 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用 |
| WO2018001430A1 (en) * | 2016-06-29 | 2018-01-04 | Science Ventures Denmark A/S | A supercapacitor and a method for expanding the voltage range of an aqueous electrolyte supercapacitor |
| HUE046449T2 (hu) | 2016-09-13 | 2020-03-30 | Allergan Inc | Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| CN110662551B (zh) | 2017-06-01 | 2023-07-18 | 伊莱利利公司 | 速效胰岛素组合物 |
| CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| CN109913422A (zh) * | 2017-12-13 | 2019-06-21 | 苏州康聚生物科技有限公司 | 一种包含肿瘤抗原识别受体的免疫细胞及其应用 |
| CA3094237A1 (en) | 2018-04-04 | 2019-10-10 | Arecor Limited | Medical infusion pump system for the delivery of an insulin compound |
| US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
| JP7204729B2 (ja) | 2018-07-25 | 2023-01-16 | アルテオゼン インコーポレイテッド | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| CR20210489A (es) * | 2019-03-25 | 2021-12-07 | Alteogen Inc | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa ph20 y un medicamento |
| CN113840921A (zh) * | 2020-01-23 | 2021-12-24 | 阿特根公司 | 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物 |
| TWI881239B (zh) * | 2020-06-09 | 2025-04-21 | 南韓商阿特根公司 | 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物 |
| TWI781415B (zh) * | 2020-06-09 | 2022-10-21 | 南韓商阿特根公司 | 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物 |
| TWI788188B (zh) * | 2020-06-09 | 2022-12-21 | 南韓商阿特根公司 | 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物 |
| CN115776909A (zh) * | 2020-07-17 | 2023-03-10 | 美国杰龙生物医药公司 | 皮下端粒酶抑制剂组合物及其使用方法 |
| CN120738156A (zh) | 2020-08-07 | 2025-10-03 | 阿特根公司 | 制备重组玻尿酸酶的方法 |
| MX2023002884A (es) | 2020-09-14 | 2023-03-31 | Boehringer Ingelheim Int | Vacuna heterologa de estimulo primario. |
| US20220233689A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Methods of treating tumors |
| CN112763610B (zh) * | 2020-12-28 | 2022-04-01 | 浙江大学 | 土壤中抗生素的检测方法 |
| RS66849B1 (sr) | 2020-12-28 | 2025-06-30 | Bristol Myers Squibb Co | Kompozicije antitela i postupci njihove upotrebe |
| CN114350691B (zh) * | 2021-03-05 | 2023-12-08 | 华熙生物科技股份有限公司 | 一种高效表达透明质酸水解酶的基因及其表达方法 |
| CN113444708B (zh) * | 2021-07-19 | 2024-02-13 | 河南赛培生物科技有限公司 | 一种用于药物皮下注射制剂的透明质酸酶突变体 |
| CN115671267A (zh) | 2021-07-23 | 2023-02-03 | 上海宝济药业有限公司 | 一种皮下抗生素药物组合物 |
| EP4380618A2 (en) | 2021-08-02 | 2024-06-12 | argenx BV | Subcutaneous unit dosage forms |
| EP4401758A1 (en) | 2021-09-14 | 2024-07-24 | Takeda Pharmaceutical Company Limited | Facilitated delivery of concentrated antibody formulations using hyaluronidase |
| EP4419663A1 (en) * | 2021-10-19 | 2024-08-28 | Pharmact Holding AG | A production of a purified modified bacterial hyaluronidase polypeptide, pharmaceutical compositions and their uses |
| AU2022376750A1 (en) * | 2021-10-29 | 2024-05-16 | Alteogen Inc. | Pharmaceutical composition comprising human hyaluronidase ph20 and drug |
| CN114634920B (zh) * | 2022-03-24 | 2024-02-27 | 江南大学 | 一种产人源透明质酸酶ph20的重组毕赤酵母及其构建方法 |
| CN114624366B (zh) * | 2022-05-16 | 2022-07-26 | 南京瑞克卫生物医药有限公司 | 一种醋酸西曲瑞克聚合物杂质的检测方法 |
| AU2023281061A1 (en) | 2022-06-02 | 2024-12-05 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| KR102774438B1 (ko) * | 2022-06-08 | 2025-02-27 | (주)한국비엠아이 | 히알루로니다제 폴리펩티드 및 이의 용도 |
| WO2024138188A1 (en) | 2022-12-22 | 2024-06-27 | Halozyme, Inc. | Hyaluronidase enzyme formulations for high volume administration |
| KR20250152101A (ko) | 2023-03-13 | 2025-10-22 | 하이델베르크 파마 리서치 게엠베하 | 암 치료에의 사용을 위한 피하 투여 항체-약물 접합체 |
| CN116272708B (zh) * | 2023-03-16 | 2023-11-14 | 海南医学院 | 一种量子点-抗体复合物微球及其制备方法、应用 |
| WO2025158277A1 (en) | 2024-01-22 | 2025-07-31 | Janssen Biotech, Inc. | Use of amivantamab to treat head and neck cancer |
| WO2025191459A1 (en) | 2024-03-11 | 2025-09-18 | Janssen Biotech, Inc. | Use of bispecific anti-egfr/c-met antibodies to treat solid tumors |
| WO2025248465A1 (en) | 2024-05-29 | 2025-12-04 | Janssen Biotech, Inc. | Treatment of locally advanced or metastatic egfr-mutated non-small cell lung cancer |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| EP0040472B1 (en) | 1980-05-20 | 1986-01-29 | Mallinckrodt, Inc. (a Delaware corporation) | Spray dried n-acetyl-p-aminophenol compositions and method for manufacture thereof |
| AU546785B2 (en) * | 1980-07-23 | 1985-09-19 | Commonwealth Of Australia, The | Open-loop controlled infusion of diabetics |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| US4769027A (en) | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| DE69026306T2 (de) | 1989-05-27 | 1996-10-17 | Seikagaku Kogyo Co Ltd | Verfahren für die Herstellung von Polyethylenglykolderivate und modifizierte Proteine. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5721348A (en) | 1990-12-14 | 1998-02-24 | University Of Connecticut | DNA encoding PH-20 proteins |
| AU668505B2 (en) | 1991-03-18 | 1996-05-09 | Scripps Research Institute, The | Oligosaccharide enzyme substrates and inhibitors: methods and compositions |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| AU7097094A (en) | 1993-06-01 | 1994-12-20 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| JP2996415B2 (ja) | 1994-03-31 | 1999-12-27 | アムジエン・インコーポレーテツド | 巨核球の成長と分化を刺激するモノｐｅｇ化ｍｇｄｆポリペプチド |
| US5795569A (en) | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US20010055563A1 (en) | 1999-09-09 | 2001-12-27 | Rhomed Incorporated | Post-labeling stabilization of radiolabeled proteins and peptides |
| US5958750A (en) | 1996-07-03 | 1999-09-28 | Inctye Pharmaceuticals, Inc. | Human hyaluronidase |
| US6461863B1 (en) | 1996-08-16 | 2002-10-08 | University Of Wyoming | Modifying insect cell gylcosylation pathways with baculovirus expression vectors |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| US6193963B1 (en) | 1996-10-17 | 2001-02-27 | The Regents Of The University Of California | Method of treating tumor-bearing patients with human plasma hyaluronidase |
| US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
| US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
| GB9803751D0 (en) | 1998-02-23 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
| ATE399809T1 (de) | 1998-03-12 | 2008-07-15 | Nektar Therapeutics Al Corp | Verfahren zur herstellung von polymerkonjugaten |
| JP2002519686A (ja) | 1998-07-03 | 2002-07-02 | ネレス・フィールド・コントロールズ・オイ | 液体物質測定方法および装置 |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| US6461802B1 (en) | 1999-08-02 | 2002-10-08 | Agfa-Gevaert | Adhesive layer for polyester film |
| WO2001046291A1 (en) | 1999-12-22 | 2001-06-28 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
| NZ522847A (en) | 2000-05-16 | 2004-11-26 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
| US6615063B1 (en) * | 2000-11-27 | 2003-09-02 | The General Hospital Corporation | Fluorescence-mediated molecular tomography |
| ATE505204T1 (de) | 2000-12-20 | 2011-04-15 | Hoffmann La Roche | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) |
| TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| KR100948532B1 (ko) | 2001-11-07 | 2010-03-23 | 넥타르 테라퓨틱스 | 분지형 중합체 및 그의 공액체 |
| KR20040040782A (ko) | 2002-11-08 | 2004-05-13 | 선바이오(주) | 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법 |
| PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| AU2004215912B2 (en) | 2003-02-26 | 2009-03-26 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| CA2517145C (en) | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20090123367A1 (en) | 2003-03-05 | 2009-05-14 | Delfmems | Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| KR100512483B1 (ko) | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
| MXPA05012307A (es) * | 2003-05-16 | 2006-07-03 | Acorda Therapeutics Inc | Mutantes que degradan proteoglicanos para tratamiento del snc. |
| KR101128320B1 (ko) | 2003-05-23 | 2012-04-12 | 넥타르 테라퓨틱스 | 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체 |
| US20050054048A1 (en) | 2003-07-29 | 2005-03-10 | Luigi Grasso | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| WO2005042753A1 (en) | 2003-10-28 | 2005-05-12 | Chesapeake Perl, Inc. | Production of human glycosylated proteins in transgenic insects |
| AU2004293471C1 (en) | 2003-11-25 | 2011-02-24 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Mutated anti-CD22 antibodies and immunoconjugates |
| PL1740154T3 (pl) | 2004-03-12 | 2009-11-30 | Biodel Inc | Kompozycje insuliny o ulepszonym wchłanianiu |
| US7112687B2 (en) | 2004-07-15 | 2006-09-26 | Indena, S.P.A. | Methods for obtaining paclitaxel from taxus plants |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| AU2006255938B2 (en) | 2005-06-09 | 2011-05-12 | Nanocarrier Co., Ltd. | Process for production of polymerized coordination compound of platinum complex |
| JP2007153797A (ja) | 2005-12-05 | 2007-06-21 | Toshitsu Kagaku Kenkyusho:Kk | 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤 |
| AU2007280398B2 (en) | 2006-08-01 | 2012-05-10 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| WO2009037566A2 (en) | 2007-06-19 | 2009-03-26 | Uvarkina Tamara P | Hyaluronidase and method of use thereof |
| CN106906196A (zh) | 2008-03-06 | 2017-06-30 | 哈洛齐梅公司 | 可溶性透明质酸酶的大规模生产 |
| TWI489994B (zh) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| US20090311237A1 (en) | 2008-04-14 | 2009-12-17 | Frost Gregory I | Combination therapy using a soluble hyaluronidase and a bisphosphonate |
| JP2011519361A (ja) | 2008-04-14 | 2011-07-07 | ハロザイム インコーポレイテッド | 修飾されたヒアルロニダーゼおよびヒアルロナン関連疾患および状態の治療における使用 |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| ES2724588T3 (es) | 2008-12-09 | 2019-09-12 | Halozyme Inc | Polipéptidos de PH20 soluble extendida y usos de los mismos |
| HUE027239T2 (en) | 2009-06-26 | 2016-10-28 | Novo Nordisk As | Preparation containing insulin, nicotinamide and arginine |
| US9084743B2 (en) * | 2009-09-17 | 2015-07-21 | Baxter International Inc. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| JP5136582B2 (ja) | 2010-03-24 | 2013-02-06 | ブラザー工業株式会社 | 現像カートリッジ |
| KR20130125753A (ko) | 2010-07-20 | 2013-11-19 | 할로자임, 아이엔씨 | 항-히알루로난제 투여와 관련된 유해 부작용의 치료 |
| US8401194B2 (en) * | 2010-10-15 | 2013-03-19 | Roche Diagnostics Operations, Inc. | Diabetes care kit that is preconfigured to establish a secure bidirectional communication link between a blood glucose meter and insulin pump |
| ES2634669T3 (es) | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
| US9149160B2 (en) | 2011-03-17 | 2015-10-06 | Evolution Technologies Inc. | Bath chair |
| WO2012136768A1 (en) * | 2011-04-08 | 2012-10-11 | Hans-Dieter Haubeck | Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth |
| AU2012271361B2 (en) | 2011-06-17 | 2017-03-02 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme |
| US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| KR20140043438A (ko) | 2011-06-17 | 2014-04-09 | 할로자임, 아이엔씨 | 히알루로난 분해 효소의 안정한 제형 |
| US20130071394A1 (en) * | 2011-09-16 | 2013-03-21 | John K. Troyer | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use |
| EA030440B1 (ru) | 2011-10-24 | 2018-08-31 | Галозим, Инк. | Сопровождающая диагностика для терапии антигиалуронановым агентом и способы ее применения |
| BR112014016195A2 (pt) * | 2011-12-30 | 2020-10-27 | Halozyme, Inc. | variantes de polipeptídio ph20, formulações e usos das mesmas |
| CN104411324A (zh) | 2012-04-04 | 2015-03-11 | 哈洛齐梅公司 | 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法 |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| TW201534726A (zh) | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ｐｈ２０玻尿酸酶變異體及其用途 |
| EP3814191A1 (en) | 2018-06-28 | 2021-05-05 | Konux GmbH | Planning of maintenance of railway |
| JP7204729B2 (ja) | 2018-07-25 | 2023-01-16 | アルテオゼン インコーポレイテッド | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| CR20210489A (es) | 2019-03-25 | 2021-12-07 | Alteogen Inc | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa ph20 y un medicamento |
| US10796453B1 (en) | 2019-06-28 | 2020-10-06 | GM Cruise Holdings, LLC | Vehicle sensor calibration system using dynamic scene |
| CA3159539A1 (en) | 2019-12-02 | 2021-06-10 | Binah.Ai Ltd | System and method for physiological measurements from optical data |
-
2012
- 2012-12-28 BR BR112014016195-0A patent/BR112014016195A2/pt not_active Application Discontinuation
- 2012-12-28 HU HUE16189970A patent/HUE047849T2/hu unknown
- 2012-12-28 LT LT16189970T patent/LT3130347T/lt unknown
- 2012-12-28 MX MX2014007966A patent/MX361727B/es active IP Right Grant
- 2012-12-28 PL PL16189970T patent/PL3130347T3/pl unknown
- 2012-12-28 EP EP12816624.6A patent/EP2797622B1/en active Active
- 2012-12-28 US US13/694,731 patent/US9447401B2/en active Active
- 2012-12-28 RS RS20191613A patent/RS59703B1/sr unknown
- 2012-12-28 SM SM20190630T patent/SMT201900630T1/it unknown
- 2012-12-28 ES ES16189970T patent/ES2749620T3/es active Active
- 2012-12-28 PT PT161899703T patent/PT3130347T/pt unknown
- 2012-12-28 SG SG10201604470TA patent/SG10201604470TA/en unknown
- 2012-12-28 SI SI201231709T patent/SI3130347T1/sl unknown
- 2012-12-28 DK DK16189970.3T patent/DK3130347T3/da active
- 2012-12-28 CN CN201280070954.9A patent/CN104244968B/zh active Active
- 2012-12-28 IL IL317266A patent/IL317266A/en unknown
- 2012-12-28 IL IL298330A patent/IL298330B1/en unknown
- 2012-12-28 CA CA2861919A patent/CA2861919C/en active Active
- 2012-12-28 EP EP16189970.3A patent/EP3130347B1/en active Active
- 2012-12-28 WO PCT/US2012/072182 patent/WO2013102144A2/en not_active Ceased
- 2012-12-28 ES ES12816624.6T patent/ES2609582T3/es active Active
- 2012-12-28 SG SG11201403714TA patent/SG11201403714TA/en unknown
- 2012-12-28 AU AU2012362141A patent/AU2012362141B2/en active Active
- 2012-12-28 EA EA201400772A patent/EA030252B9/ru not_active IP Right Cessation
- 2012-12-28 JP JP2014550526A patent/JP6067746B2/ja active Active
- 2012-12-28 DK DK12816624.6T patent/DK2797622T3/en active
-
2014
- 2014-06-17 IL IL233192A patent/IL233192B/en active IP Right Grant
- 2014-06-27 MX MX2018012394A patent/MX2018012394A/es unknown
-
2016
- 2016-08-02 US US15/226,489 patent/US10865400B2/en active Active
- 2016-12-21 JP JP2016247708A patent/JP6422933B2/ja active Active
-
2017
- 2017-10-11 AU AU2017245352A patent/AU2017245352B2/en active Active
-
2019
- 2019-12-10 CY CY20191101301T patent/CY1122532T1/el unknown
- 2019-12-13 HR HRP20192249TT patent/HRP20192249T1/hr unknown
-
2020
- 2020-03-19 US US16/824,572 patent/US11041149B2/en active Active
- 2020-05-20 IL IL274798A patent/IL274798B/en active IP Right Grant
- 2020-06-25 US US16/912,590 patent/US11066656B2/en active Active
-
2021
- 2021-02-18 IL IL280949A patent/IL280949B2/en unknown
- 2021-05-21 US US17/327,568 patent/US12091692B2/en active Active
- 2021-05-21 US US17/327,586 patent/US12037618B2/en active Active
-
2022
- 2022-12-12 US US18/064,886 patent/US12049652B2/en active Active
- 2022-12-15 US US18/066,960 patent/US12054758B2/en active Active
- 2022-12-19 US US18/068,418 patent/US12110520B2/en active Active
- 2022-12-19 US US18/068,443 patent/US12104184B2/en active Active
- 2022-12-19 US US18/068,218 patent/US12060590B2/en active Active
- 2022-12-19 US US18/068,327 patent/US12123035B2/en active Active
- 2022-12-21 US US18/069,651 patent/US20230287381A1/en not_active Abandoned
-
2023
- 2023-06-20 US US18/338,189 patent/US11952600B2/en active Active
- 2023-06-22 US US18/339,829 patent/US12077791B2/en active Active
- 2023-06-23 US US18/340,482 patent/US12018298B2/en active Active
- 2023-06-23 US US18/340,802 patent/US12152262B2/en active Active
- 2023-06-23 US US18/340,786 patent/US12371685B2/en active Active
-
2024
- 2024-03-08 US US18/599,428 patent/US12104185B2/en active Active
- 2024-05-09 US US18/659,215 patent/US12195773B2/en active Active
- 2024-06-28 US US18/759,577 patent/US20250154488A1/en not_active Abandoned
- 2024-07-19 US US18/778,554 patent/US12264345B1/en active Active
- 2024-10-22 US US18/922,889 patent/US20250051747A1/en active Pending
-
2025
- 2025-03-05 US US19/071,264 patent/US20250197835A1/en active Pending
- 2025-03-05 US US19/071,345 patent/US20250197836A1/en active Pending
- 2025-03-05 US US19/071,005 patent/US20250197832A1/en active Pending
- 2025-03-05 US US19/071,055 patent/US20250197833A1/en active Pending
- 2025-03-05 US US19/071,092 patent/US20250197834A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504666A5 (enExample) | ||
| JP2014526441A5 (enExample) | ||
| Rave et al. | Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro | |
| US20180000898A1 (en) | Method of Treating or Ameliorating Type 1 Diabetes Using FGF21 | |
| US9359405B2 (en) | Antagonists of the interleukin-1 receptor | |
| KR102040752B1 (ko) | 류마티스 관절염을 치료 또는 예방하는 약물 제조에서 폴리펩타이드의 응용 | |
| US20120083453A1 (en) | Treatment using neublastin polypeptides | |
| EP1395279B1 (en) | Use of neublastin polypeptides for treating neuropathic pain | |
| CN103193878B (zh) | 突变hFGF-21蛋白成熟肽及其与聚乙二醇的交联物以及它们的应用 | |
| AU2017357327B2 (en) | Pegylated endostatin analogue and application thereof | |
| AU2008324426B2 (en) | Novel neurturin conjugates for pharmaceutical use | |
| KR20190026813A (ko) | 시스틴의 인간-효소 매개된 고갈 | |
| JP6320648B1 (ja) | 血糖降下化合物 | |
| US10947296B2 (en) | Fusion protein Slit2D2(C386S)-HSA and use thereof in treatment of fibrotic diseases | |
| CN100391979C (zh) | 一种单甲氧基聚乙二醇-胰岛素复合物及其制备方法 | |
| CN102120755B (zh) | 一种棕色脂肪组织靶向性多肽及其应用 | |
| Roy et al. | Overview of novel routes of insulin: current status | |
| CN107949372A (zh) | 烯醇酶1（Eno1）组合物及其用途 | |
| US8802824B2 (en) | Modified recombinant human endostatin and uses thereof | |
| Patil et al. | Colloidal carriers for noninvasive delivery of insulin | |
| WO2020143548A1 (zh) | 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物 | |
| JP2020527573A (ja) | 強皮症関連血管障害を治療または改善するための組成物および方法 | |
| CN103788179B (zh) | 多肽小分子及其在制备防治膀胱过度活跃药物中的应用 | |
| CN103656639A (zh) | 不规则趋化因子的中和抗体用于制备消除糖尿病心肾功能损害不良代谢记忆的药物的用途 | |
| Patel et al. | Perioperative changes in liver function tests following hepatic resection surgery: A-807 |